https://www.selleckchem.com/pr....oducts/17-AAG(Geldan
The ever-increasing sensitivity of assay systems, the lack of quality control of samples combined with the almost complete reliance on antibody-based assay platforms represent important unsolved issues as false negative results can lead to false clinical decision making and adverse outcomes. This article serves as a commentary on the state of mTBI biomarkers and the landscape of significant challenges. We highlight and discusses several biological and methodological "known unknowns" and close with some practical recommendat
Like
Comment
Share
